CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
erlotinib hydrochloride +2 moredrug
Likely dose
erlotinib hydrochloride 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00445588
NCT00445588Phase 2Completed
CompareCT.gov

A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)·interventional·Posted Mar 9, 2007·Updated Apr 27, 2016

In Brief

A Phase 2 clinical trial evaluating erlotinib hydrochloride, sorafenib tosylate, and 1 other intervention for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 56 participants across 9 sites.

Detailed Summary

This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme. Erlotinib and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving erlotinib together with sorafenib may kill more tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2007
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.3 years ago

Interventions

erlotinib hydrochloridedrug

150mg Given orally once daily

sorafenib tosylatedrug

400mg Given orally twice daily

pharmacological studyother

Correlative studies